Immunovirotherapy for the treatment of glioblastoma

We have recently described a new murine model of glioblastoma, generated by the implantation of syngeneic glioblastoma stem cells into immunocompetent mice, that recapitulates the salient histopathological and immunological features of the human disease. We employed this model to demonstrate the mul...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheema, Tooba A, Fecci, Peter E, Ning, Jianfang, Rabkin, Samuel D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3929360/
https://www.ncbi.nlm.nih.gov/pubmed/24575383
http://dx.doi.org/10.4161/onci.27218
_version_ 1782304385507786752
author Cheema, Tooba A
Fecci, Peter E
Ning, Jianfang
Rabkin, Samuel D
author_facet Cheema, Tooba A
Fecci, Peter E
Ning, Jianfang
Rabkin, Samuel D
author_sort Cheema, Tooba A
collection PubMed
description We have recently described a new murine model of glioblastoma, generated by the implantation of syngeneic glioblastoma stem cells into immunocompetent mice, that recapitulates the salient histopathological and immunological features of the human disease. We employed this model to demonstrate the multifaceted activity of an oncolytic herpes simplex virus genetically modified to express interleukin-12, G47∆-IL12.
format Online
Article
Text
id pubmed-3929360
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-39293602014-02-26 Immunovirotherapy for the treatment of glioblastoma Cheema, Tooba A Fecci, Peter E Ning, Jianfang Rabkin, Samuel D Oncoimmunology Author's View We have recently described a new murine model of glioblastoma, generated by the implantation of syngeneic glioblastoma stem cells into immunocompetent mice, that recapitulates the salient histopathological and immunological features of the human disease. We employed this model to demonstrate the multifaceted activity of an oncolytic herpes simplex virus genetically modified to express interleukin-12, G47∆-IL12. Landes Bioscience 2014-01-01 /pmc/articles/PMC3929360/ /pubmed/24575383 http://dx.doi.org/10.4161/onci.27218 Text en Copyright © 2014 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Cheema, Tooba A
Fecci, Peter E
Ning, Jianfang
Rabkin, Samuel D
Immunovirotherapy for the treatment of glioblastoma
title Immunovirotherapy for the treatment of glioblastoma
title_full Immunovirotherapy for the treatment of glioblastoma
title_fullStr Immunovirotherapy for the treatment of glioblastoma
title_full_unstemmed Immunovirotherapy for the treatment of glioblastoma
title_short Immunovirotherapy for the treatment of glioblastoma
title_sort immunovirotherapy for the treatment of glioblastoma
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3929360/
https://www.ncbi.nlm.nih.gov/pubmed/24575383
http://dx.doi.org/10.4161/onci.27218
work_keys_str_mv AT cheematoobaa immunovirotherapyforthetreatmentofglioblastoma
AT feccipetere immunovirotherapyforthetreatmentofglioblastoma
AT ningjianfang immunovirotherapyforthetreatmentofglioblastoma
AT rabkinsamueld immunovirotherapyforthetreatmentofglioblastoma

Ejemplares similares